Cartesian Therapeutics, Inc. Stock Split Ratio
Cartesian Therapeutics, Inc. (RNAC) had Stock Split Ratio of 3.33% as of 2024-04-04, per its 10-K filed 2026-03-09.
Financial Statements › Notes › Stockholders' Equity Note
us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 · last filed 2026-03-09
- 2024-04-04: Stockholders' Equity Note, Stock Split, Conversion Ratio 3.33%.
- 2016-06-07: Stockholders' Equity Note, Stock Split, Conversion Ratio 390.00%; Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed 25.64%.
| Period end | Stockholders' Equity Note, Stock Split, Conversion Ratio | Stockholders' Equity Note, Stock Split, Conversion Ratio as first filed |
|---|---|---|
| 2024-04-04 | 3.33% 10-K · filed 2026-03-09 | |
| 2016-06-07 | 390.00% 10-K · filed 2018-03-15 | 25.64% 10-K · filed 2017-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| NATURES SUNSHINE PRODUCTS INC (NATR) | United States | $0.228B | 20.51 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B | |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |